Our findings provide new insights into the molecular mechanisms of TUSC2-mediated tumor suppression, and suggest that the therapeutic activity of TUSC2 could extend the use of erlotinib to lung cancer patients with wildtype EGFR. Here, EGFR is linked to lung cancer.